Skip to main content

Advertisement

Log in

Suboptimal statin adherence and discontinuation in primary and secondary prevention populations

Should we target patients with the most to gain?

  • Original Articles
  • Published:
Journal of General Internal Medicine Aims and scope Submit manuscript

Abstract

OBJECTIVES: To compare statin nonadherence and discontinuation rates of primary and secondary prevention populations and to identify factors that may affect those suboptimal medication-taking behaviors.

DESIGN: Retrospective cohort utilizing pharmacy claims and administrative databases.

SETTING: A midwestern U.S. university-affiliated hospital and managed care organization (MCO).

PATIENTS: Non-Medicaid MCO enrollees, 18 years old and older, who filled 2 or more statin prescriptions from January 1998 to November 2001; 2,258 secondary and 2,544 primary prevention patients were identified.

MEASUREMENTS: Nonadherence was assessed by the percent of days without medication (gap) over days of active statin use, a measurement known as cumulative multiple refill-interval gap (CMG). Discontinuation was identified by cessation of statin refills prior to the end of available pharmacy claims data.

RESULTS: On average, the primary and secondary groups went without medication 20.4% and 21.5% of the time, respectively (P=.149). Primary prevention patients were more likely to discontinue statin therapy relative to the secondary prevention cohort (relative risk [RR], 1.24; 95% confidence interval [CI], 1.08 to 1.43). Several factors influenced nonadherence and discontinuation. Fifty percent of patients whose average monthly statin copayment was <$10 discontinued by the end of follow-up (3.9 years), whereas 50% of those who paid >$10 but ≤$20 and >$20 discontinued by 2.2 and 1.0 years, respectively (RR, 1.39 and 4.30 relative to <$10 copay, respectively).

CONCLUSIONS: Statin nonadherence and discontinuation was suboptimal and similar across prevention categories. Incremental efforts, including those that decrease out-of-pocket pharmaceutical expenditures, should focus on improving adherence in high-risk populations most likely to benefit from statin use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Shepherd J, Cobe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–7.

    Article  PubMed  CAS  Google Scholar 

  2. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study result. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991;151:43–9.

    Article  PubMed  CAS  Google Scholar 

  3. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of ASCAPS/TexCAPS. JAMA. 1998;279:1615–22.

    Article  PubMed  CAS  Google Scholar 

  4. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.

    Article  Google Scholar 

  5. The LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–57.

    Article  Google Scholar 

  6. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–9.

    Article  PubMed  CAS  Google Scholar 

  7. Kumana CR, Cheung B, Lauder IJ. Gauging the impact of statins using number needed to treat. JAMA. 1999;282:1899–901.

    Article  PubMed  CAS  Google Scholar 

  8. McDermott MM, Schmitt B, Wallner E. Impact of medication non-adherence on coronary heart outcomes: a critical review. Arch Intern Med. 1997;157:1921–9.

    Article  PubMed  CAS  Google Scholar 

  9. Mäenpää H, Heinonen OP, Manninen V. Medication compliance and serum lipid changes in the Helsinki Heart Study. Br J Clin Pharmacol. 1991;32:409–15.

    PubMed  Google Scholar 

  10. The West of Scotland Coronary Prevention Study Group. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J. 1997;18:1718–24.

    Google Scholar 

  11. Andrade SE, Walker AM, Gottleib LK, et al. Discontinuation of antihyperlipidemic drugs—do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995;332:1125–31.

    Article  PubMed  CAS  Google Scholar 

  12. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279:1458–62.

    Article  PubMed  CAS  Google Scholar 

  13. Sung JCY, Nichol MB, Venturini F, Bailey KL, McCombs JS, Cody M. Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. Am J Manag Care. 1998;4:1421–30.

    PubMed  CAS  Google Scholar 

  14. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455–61.

    Article  PubMed  Google Scholar 

  15. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288:462–7.

    Article  PubMed  Google Scholar 

  16. Taylor H, Leitman R. Out-of-pocket costs are a substantial barrier to prescription drug compliance. Health Care News. November 20, 2001.

  17. Reed-Haldy-McIntosh for AARP. Prescription Drug Use Among Persons Age 45+. Survey; April 2002.

  18. Cunningham PJ. Affording Prescription Drugs: Not Just a Problem for the Elderly. Center for Studying Health System Change. Washington, DC: Research Report No. 5; April 2002.

  19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.

    Article  Google Scholar 

  20. Health Plan Employer Data and Information Set (HEDIS). Cholesterol Management After Acute Cardiovascular Events. Washington, DC: National Committee for Quality Assurance; 2002.

    Google Scholar 

  21. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records: description and validation. Med Care. 1988;26:814–23.

    Article  PubMed  CAS  Google Scholar 

  22. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105–16.

    Article  PubMed  CAS  Google Scholar 

  23. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002;105:1446–52.

    Article  PubMed  CAS  Google Scholar 

  24. Thomas M, Mann J. Increased thrombotic vascular events after change of statin. Lancet. 1998;352:1830–1.

    Article  PubMed  CAS  Google Scholar 

  25. White TJ, Chang E, Leslie S, et al. Patient adherence with HMG reductase inhibitor therapy among users of two types of prescription services. J Manag Care Pharm. 2002;8:186–91.

    Google Scholar 

  26. Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow-up study. Heart. 2002;88:229–33.

    Article  PubMed  CAS  Google Scholar 

  27. Joyce GF, Escarce JJ, Solomon MD, Goldman DP. Employer drug benefit plans and spending on prescription drugs. JAMA 2002;288:1733–9.

    Article  PubMed  Google Scholar 

  28. Motheral BR, Henderson R. The effect of a copay increase on pharmaceutical utilization, expenditures, and treatment continuation. Am J Manag Care. 1999;5:1383–94.

    PubMed  CAS  Google Scholar 

  29. Fendrick AM, Smith DG, Chernew ME, Shaw SN. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care. 2001;7:861–7.

    PubMed  CAS  Google Scholar 

  30. Nelson K, Norris K, Mangione CM. Disparities in the diagnosis and pharmacologic treatment of high serum cholesterol by race and ethnicity. Arch Intern Med. 2002;162:929–35.

    Article  PubMed  Google Scholar 

  31. Salganicoff A, Beckman JZ, Wyn R, Ojeda VD. Women’s Health in the United States: Health Coverage and Access to Care. Report by The Henry J. Kaiser Foundation; May 2002.

  32. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–10.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ellis, J.J., Erickson, S.R., Stevenson, J.G. et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J GEN INTERN MED 19, 638–645 (2004). https://doi.org/10.1111/j.1525-1497.2004.30516.x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1111/j.1525-1497.2004.30516.x

Key words

Navigation